We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test to Diagnose Skin Cancer May Help Avoid Invasive Skin Biopsies

By LabMedica International staff writers
Posted on 21 Apr 2022
Print article
Image: A blood test could help diagnose skin cancer (Photo courtesy of Pexels)
Image: A blood test could help diagnose skin cancer (Photo courtesy of Pexels)

Melanoma is one of the most aggressive skin cancers due to its potential to metastasize widely in the body. The risk of metastasis is increased with later detection and increased thickness of the primary lesion, thus early identification/surgical removal is critical for higher survival rates. Recent advances in liquid biopsy have proposed less-invasive alternatives for cancer diagnosis and monitoring using minimal invasion at sample collection, and circulating tumor cells (CTCs) have been considered a promising blood-based surrogate marker of primary tumors. Now, new research indicates that testing an individual’s blood can reveal the presence of CTCs. Such tests may allow patients to forego invasive skin biopsies to determine whether they have skin cancer.

For applications in treatment monitoring, researchers at the University of Michigan (Ann Arbor, MI, USA) investigated melanoma CTC quantification and molecular profiling using a novel microfluidic device, MelanoBean (MB) chip. The MB chip is a newly optimized platform of the previously reported OncoBean microfluidic device for melanoma. The researchers showed that the test, which uses the Melanoma-specific OncoBean platform conjugated with melanoma-specific antibodies, can be used not only to diagnose melanoma but also to evaluate whether all cancer cells have been successfully removed after skin cancer surgery.

"This is the first comprehensive study of circulating tumor cells - or CTCs - to evaluate the efficacy of surgery using microfluidic systems in melanoma, including changes in the number of CTCs, CTC cluster configuration, and gene expression profiling,” said first author, Yoon-Tae Kang, PhD.

“CTCs have the potential to pinpoint treatment resistance and recurrence, and can be a valuable biomarker to non-invasively monitor for disease progression,” added corresponding author Sunitha Nagrath, PhD.

Related Links:
University of Michigan 

Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
H.pylori DNA Extraction Kit
Savvygen Stool NA Extraction Kit
New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The new assays will run on the QIAcuity digital PCR (dPCR) platform (Photo courtesy of QIAGEN)

New Digital PCR Assays Enable Accurate and Sensitive Detection of Critical Pathogens

QIAGEN (Venlo, the Netherlands) has introduced 100 new assays for its QIAcuity digital PCR (dPCR) platform, aimed at advancing research in areas such as cancer, inherited genetic disorders, and infectious... Read more

Pathology

view channel
Image: The new AI technology more precisely predicts the risk of getting breast cancer (Photo courtesy of William Brøns Petersen)

AI Technology Accurately Predicts Breast Cancer Risk Via ‘Zombie Cells’

Breast cancer remains one of the most common cancers worldwide, causing 670,000 deaths in 2022. A key aspect of assessing cancer risk involves identifying dying cells. A new study has demonstrated that... Read more

Industry

view channel
Image: International expert meeting for trends and innovations in laboratory medicine - the MEDICA LABMED FORUM at MEDICA (Photo courtesy of Constanze Tillmann/Messe Düsseldorf)

MEDICA LABMED FORUM 2024: International Experts Meet to Discuss Trending Topics in Laboratory Medicine

At MEDICA (Düsseldorf, Germany), the world’s premier trade fair for the healthcare industry and medical technology sector, this year’s event (November 11–14) will focus on the most exciting medical advancements.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.